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In a second approach, 2 clinical samples (GT 1a & GT 1b) 
were diluted to 100 and 25 IU/ml and tested as described 
above. While the result range for WHO 100 IU/ml repli-
cates across all laboratories was similar in this analysis, 
the CVs of each laboratory ranged from 19.3 to 25.6 % for 
RealTime laboratories and were lower than CVs of CTM 
v2 laboratories with a range of 26.1–47.3 %, respectively, 
and also in comparison with the CV of the HPS reference 
laboratory (34.9 %). At WHO standard dilution of 25 IU/
ml, 24 replicates were quantified by RealTime compared to 
8 replicates with CTM v2. Results of clinical samples again 
revealed a higher variation of CTM v2 results as com-
pared to RealTime values. (CVs at 100 IU/ml: RealTime: 
13.1–21.0 % and CTM v2: 15.0–32.3 %; CVs at 25 IU/ml: 
RealTime 17.6–34.9 % and CTM v2 28.2–54.9 %). These 
findings confirm the superior precision of RealTime versus 
CTM v2 at low-level viremia even across different labora-
tories including the new clinical decision point at 25 IU/ml. 
A highly precise monitoring of HCV viral load during ther-
apy will remain crucial for patient management with regard 
to futility rules, therapy efficacy and SVR.
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Introduction
To date, the most widely used HCV RNA quantification 
assays are the Abbott RealTime HCV assay (RealTime) 
and the Roche COBAS AmpliPrep/COBAS TaqMan HCV 
test version 2 (CTM v2). They were calibrated with histori-
cal WHO standards (2nd) and may vary in sensitivity and 
precision depending on genotypes and particularly in the 
setting of low-level viremia, as previously reported [1–3]. 
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A major role in DAA therapy (direct acting antivirals) was 
assigned to HCV RNA monitoring not only for investigat-
ing initial viral load but also for assessing patient adher-
ence, sustained virological response (SVR; defined as HCV 
RNA < 25 IU/ml in DAA registration trials) and to follow 
stopping rules at 25 IU/ml for the compounds Simeprevir 
and Daclatasvir or even HCV RNA detectability or unde-
tectability at certain points of time during therapy [4–6, 8, 
9]. Viral loads below or above these thresholds are intended 
to guide therapy decision, in particular at the end of treat-
ment. The clinical decision points were implemented using 
the manual Roche High Pure System/COBAS TaqMan 
assay (HPS) which, however, is rarely used in clinical 
routine.
The comparison of six commercially available HCV 
RNA assays (one laboratory per assay) revealed a substan-
tial variety in assay precision at low viremic levels in par-
ticular at 25 and 100 IU/ml [7]. Additionally, substantial 
differences in quantification were also described between 
the HPS reference assay, which was used to establish the 
clinical decision points in clinical studies, and some assay 
comparators in this recent analysis [7].
In order to confirm the results of this initial HCV low-
level viremia (LLV) study that used a one-laboratory-per-
assay approach and in order to assess laboratory-specific 
biases, the present study focussed on the assessment of pre-
cision and detection rates of RealTime and CTM v2 results 
obtained by three independent laboratories each (multiple 
laboratories per assay) and using diluted 4th HCV WHO 
Standard samples as well as low viremic clinical samples 
near detection limits of chronically HCV-infected patients.
Materials and methods
Dilutions were prepared from the 4th WHO standard 
(NIBSC code: 06/102, genotype 1a) to achieve nominal 
concentrations of 100, 25 and 10 IU/ml using HCV-nega-
tive BaseMatrix (Seracare Life Sciences; HCV negativity 
was confirmed by using the Abbott RealTime HCV assay). 
For each participating laboratory, fifteen aliquots of each 
dilution level were prepared which were treated identically 
and underwent the same freeze-thawing cycles. Samples 
were transported on dry ice to the participating laboratories 
and successfully delivered in a frozen state.
Seven different laboratories participated in this study 
with 3 laboratories using RealTime (PZB Aachen, Ger-
many/University of Essen, Germany/University of Basel, 
Switzerland), 3 laboratories using CTM v2 (University of 
Frankfurt, Germany/MHH Hannover, Germany/University 
Hospital Zurich, Switzerland) and 1 laboratory using HPS 
(University of Frankfurt, Germany). Assay characteristics 
as provided by the manufacturer are listed in Table 1.
In each laboratory, three aliquots of each dilution were 
tested in five independent runs, respectively. Medians, 
coefficients of variation (CV) and their confidence inter-
vals were determined for 100 IU/ml dilutions and detection 
rates for 25 and 10 IU/ml dilutions.
In a second approach, two clinical samples (one geno-
type 1a and one genotype 1b sample) were diluted in Base-
Matrix to concentrations of 100 and 25 IU/ml and were 
transported to all participating centres. On each system, 
three replicates of each concentration were tested in five 
independent runs (15 aliquots in total), respectively, and 
CV values, confidence intervals as well as medians were 
determined. The initial HCV RNA concentrations of the 
clinical samples had been determined with the Abbott Real-
Time HCV system prior to dilution.
CVs were only calculated if at least 2 of 3 replicates 




Assay result variation for WHO standard replicates
The overall testing results of WHO standard replicates at 
nominal concentrations of 100 and 25 IU/ml are shown in 
Fig. 1a, b. Results of the different laboratories are differ-
entiated by blue, green and red colour. While the overall 
result range across all laboratories for 100 IU/ml replicates 
was similar for CTM v2 and RealTime in this analysis 
(Fig. 1: all colours), the CVs of the individual laborato-
ries were lower across RealTime results with a range of 
19.3–25.6 % compared to CVs of CTM v2 laboratories 
with a range of 26.1–47.3 % and the HPS laboratory with 
a CV of 34.9 % (Table 2). As shown in Table 2, overall 
median values across all replicates at 100 IU/ml and across 
all laboratories were similar for CTM v2 (56 IU/ml; range 
22–72 IU/ml per laboratory) and RealTime (54 IU/ml; 
range 31–79 IU/ml per laboratory) and differed moderately 
Table 1  Assay characteristics as provided by manufacturers
LLOQ lower limit quantification, LOD limit of detection
CTM v2 HPS RealTime
Manufacturer Roche Roche Abbott
Reference standard 2nd WHO 2nd WHO 2nd WHO
Input volume 0.5 ml 0.5 ml 0.5 ml
Target region 5′UTR 5′UTR 5′UTR
LLOQ 15 IU/ml 25 IU/ml 12 IU/ml
LOD 15 IU/ml ~9.3–16.1 IU/ml 12 IU/ml
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from HPS median in this analysis (83 IU/ml) (Table 2). As 
shown in Fig. 1b, three-times more replicates at 25 IU/ml 
were quantified with RealTime (24) than with CTM v2 (8), 
with one CTM v2 centre (blue colour) and one RealTime 
centre (red colour) quantifying only one replicate each. 
In total, two replicates were quantified above 25 IU/ml in 
the HPS centre compared to two replicates by RealTime 
and none by CTM v2. Due to the low number of quantified 
replicates, a calculation of CV values at 25 IU/ml was not 
possible.




















































Fig. 1  Total WHO standard variation analysis was performed in trip-
licates in 5 independent runs (3 × 5 replicates) for each participating 
centre, as indicated by different marks. a WHO standard replicates 
with a nominal concentration of 100 IU/ml (dotted line). b WHO 
standard replicates with a nominal concentration of 25 IU/ml
Table 2  Median and CV data 
for the WHO dilution at 100 IU/
ml nominal concentration
* All values in increasing order independent of laboratory




CV % per laboratory*
(95 % Confidence interval)






HPS 83 83 34.9  
(24.9–59.2)






Table 3  Detection rates for 4th 
WHO replicates with nominal 
concentrations of 25 and 10 IU/
ml
* One replicate missing due to technical issues
Assay 25 IU/ml nominal concentration 10 IU/ml nominal concentration
Not det. Det. < LOQ ≥LOQ Not det. Det. < LOQ ≥LOQ
HPS (total) 0/15 (0 %) 13/15 (87 %) 2/15 (13 %) 3/15 (20 %) 12/15 (80 %) 0/15 (0 %)
 Centre #1 0 13 2 3 12 0
CTM v2 1/45 (2 %) 36/45 (80 %) 8/45 (18 %) 10/45 (22 %) 34/45 (76 %) 1/45 (2 %)
 Centre #2 1 13 1 6 9 0
 Centre #3 0 10 5 1 13 1
 Centre #4 0 13 2 3 12 0
RealTime 0/44* (0 %) 20/44* (45 %) 24/44* (55 %) 3/45 (7 %) 40/45 (89 %) 2/45 (4 %)
 Centre #5 0 5 10 2 13 0
 Centre #6 0 2 13 1 12 2
 Centre #7 0 13 1 0 15 0
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Analysis of assay detection rates for WHO standard 
replicates
Furthermore, the ability of each laboratory and each assay 
to detect HCV RNA in 15 WHO replicates at nominal con-
centrations of 25 and 10 IU/ml, respectively, was analysed 
(Table 3).
Overall, in nearly all 25 IU/ml replicates, HCV RNA 
was detected by CTM v2, HPS and RealTime. However, 
the amount of quantified replicates differed between CTM 
v2 (18 %) and RealTime (55 %). HPS, which has a limit 
of quantification of 25 IU/ml, quantified 13 % of 15 rep-
licates. For replicates at 10 IU/ml, 22 % were not detected 
by CTM v2 centres compared to 7 % by RealTime labo-
ratories. The HPS reference centre did not detect 20 % of 
replicates. Overall detection rates were 97 % for RealTime, 
88 % for CTM v2 and 90 % for HPS.
Analysis of assay precision and quantification of replicates 
of clinical samples with genotypes 1a and 1b
The overall assay variations in clinical genotype 1 samples 
at nominal concentration of 100 and 25 IU/ml are illustrated 
in Fig. 2. As already shown for WHO standard replicates, 
this analysis confirmed differences in precision across the 
evaluated assays independent of the participating centres 
(Fig. 2). Results from clinical samples revealed higher pre-
cision and lower CVs for RealTime as compared to CTM v2 
(Table 4). The calculated CVs obtained across RealTime 
laboratories ranged from 13.1 to 21.0 % for replicates at 
100 IU/ml and from 17.6 to 34.9 % for those at 25 IU/ml. 
In comparison, the calculated CVs obtained across CTM v2 
laboratories ranged from 15.0 to 32.3 % at 100 IU/ml and 
were particularly higher for replicates at 25 IU/ml with CVs 
of 28.2–54.9 %. The CVs for HPS were 17.7–23.6 % at 
100 IU/ml and 22.8–42.5 % at 25 IU/ml (Table 4).
In general, results obtained with CTM v2 and HPS when 
analysing the genotype 1b replicates at 25 IU/ml had higher 
coefficients of variation than corresponding genotype 1a 
results.
Median values for genotype 1a and 1b replicates at 100 
and 25 IU/ml nominal concentrations across the participat-
ing laboratories are listed in Table 4. Compared to geno-
type 1b replicates, median values of genotype 1a replicates 
measured by HPS or CTM v2 showed discrepant quantifi-
cation results relative to RealTime results (Table 4).
Fig. 2  Variability charts of 15 replicates for each of the clinical gen-
otype 1a sample (a, b) and genotype 1b sample (c, d) at nominal con-
centrations of 100 and 25 IU/ml, respectively. Numbers on the x-axis 
represent the different laboratories (1–3 represent RealTime centres, 
4–6 represent CTM v2 centres, 7 represents the HPS reference centre)
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Discussion
The results of this multicentre-per-assay study confirm and 
amend the conclusions of the previously reported initial 
investigation which was based on a one-laboratory-per-
assay approach [7]. The intention of this study was to focus 
particularly on very low viremic specimens near the clini-
cal cut-off of 25 IU/ml in a more comprehensive setting. 
RealTime demonstrated the highest detection rate (97 vs. 
90 % for HPS and 88 % for CTM v2) in detecting WHO 
standard samples with nominal concentrations of 25 IU/ml 
and below. This corresponds to the ranking in the previous 
one-laboratory-per-assay study with standard dilutions at 
25, 10 and 5 IU/ml. In the clinical sample analysis of gen-
otypes 1a and 1b, intra-assay variation was consistently 
lower for RealTime (CVs at 100 and 25 IU/ml ranged from 
13–21 % and 16–35 %, respectively) as compared to CTM 
v2 (15–32 and 28–55 %, respectively) and HPS (18–24 
and 23–43 %, respectively), indicating a higher precision 
of this assay especially at a low nominal concentrations of 
25 IU/ml. Despite the slightly different study design of the 
initial HCV LLV study with 10 replicates tested individu-
ally in 10 independent runs [7], results of this multicentric 
study are in line with the mean CV results obtained from 
the initial HCV LLV study (18 % at 100 IU/ml and 27 % 
at 25 IU/ml for RealTime, 32 and 53 % for CTM v2, and 
32 and 48 % for HPS, respectively).
In registration trials for the new direct acting antivi-
rals that were approved since 2014, SVR was consist-
ently defined as HCV RNA < 25 IU/ml (either detected 
or undetected). Thus, a high precision at 25 IU/ml is of 
major importance to properly assess SVR. Furthermore, 
previously observed differences of quantification levels 
across assays were confirmed also in this multicentre-per-
assay setting. This should be taken into consideration when 
switching assays during therapy and a comparison of quan-
tification is suggested in this case.
Current guidelines of the European Association for the 
Study of the Liver (EASL) continue to recommend moni-
toring of viral load also in IFN-free regimens to assess 
patient adherence and therapy efficacy [8, 9]. Newer com-
pounds and additional substances may lead to a simplifica-
tion of virological management in HCV treatment in the 
future. However, it might also take several years for these 
compounds to become available and refundable especially 
in resource-limited countries.
Table 4  Median and CV data for clinical genotype 1a and 1b samples
* All values in increasing order independent of laboratory
Genotype 1a
Median per laboratory (IU/ml)* Overall median (IU/ml) CV % per laboratory*
(95 % Confidence interval)
GT1a 100 IU/ml
 CTM v2 141 194 202 184 15.0 (10.9–23.9) 21.7 (15.7–35.2) 23.4 (16.9–38.2)
 HPS 269 269 23.6 (17.1–38.5)
 RealTime 84 87 119 98 13.1 (9.4–21.3) 18.3 (13.2–30.1) 21.0 (15.2–34.0)
GT1a 25 IU/ml
 CTM v2 38 42 46 39 28.2 (20.2–46.6) 37.5 (26.0–67.9) 42.2 (29.4–76.0)
 HPS 66 66 22.8 (16.5–37.1)
 RealTime 20 23 36 24 17.6 (12.8–28.3) 20.6 (14.9–33.3) 22.1 (15.8–36.7)
Genotype 1b
Median per laboratory (IU/ml)*Overall median (IU/ml) CV % per laboratory*
(95 % Confidence interval)
GT1b 100 IU/ml
 CTM v2 158 169 171 166 18.9 (13.7–30.5) 24.1 (17.4–39.4) 32.3 (23.1–54.2)
 HPS 198 198 17.7 (12.9–28.4)
 RealTime 87 96 123 97 15.7 (11.4–25.1) 18.8 (13.6–30.3) 19.4 (14.1–31.1)
GT1b 25 IU/ml
 CTM v2 28 29 40 31 41.9 (29.2–75.2) 50.3 (34.5–94.5) 54.9 (37.4–106.3)
 HPS 34 34 42.5 (28.0–90.7)
 RealTime 17 19 38 22 16.2 (11.6–27.2) 27.7 (19.7–46.8) 34.9 (24.6–60.7)
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Conclusions
Presumably, quantification assays with high accuracy and 
precision will have their clinical relevance for the upcom-
ing years since only one single measurement is used to 
assess SVR or to decide if a patient is eligible to continue 
an expensive antiviral therapy.
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